Sarasin & Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $133M | Sell |
110,831
-11,349
| -9% | -$11.6M | 1.56% | 23 |
|
|
2026
Q1 | $112M | Sell |
122,180
-9,317
| -7% | -$9.45M | 1.37% | 26 |
|
|
2025
Q4 | $141M | Sell |
131,497
-8,858
| -6% | -$8.47M | 1.47% | 29 |
|
|
2025
Q3 | $102M | Sell |
140,355
-97,438
| -41% | -$72.5M | 1% | 31 |
|
|
2025
Q2 | $185M | Buy |
237,793
+9,735
| +4% | +$7.56M | 1.85% | 23 |
|
|
2025
Q1 | $188M | Sell |
228,058
-27,437
| -11% | -$22.8M | 2.04% | 22 |
|
|
2024
Q4 | $197M | Buy |
255,495
+15,260
| +6% | +$12.6M | 2.18% | 18 |
|
|
2024
Q3 | $213M | Sell |
240,235
-74,186
| -24% | -$66.7M | 2.01% | 24 |
|
|
2024
Q2 | $285M | Buy |
314,421
+38,597
| +14% | +$30.9M | 2.52% | 18 |
|
|
2024
Q1 | $215M | Buy |
275,824
+28,335
| +11% | +$20.2M | 2.11% | 21 |
|
|
2023
Q4 | $144M | Buy |
247,489
+237,478
| +2,372% | +$139M | 1.59% | 27 |
|
|
2023
Q3 | $5.38M | Buy |
+10,011
| New | +$5.16M | 0.07% | 61 |
|
|
2023
Q2 | – | Sell |
-29,396
| Closed | -$10.1M | – | 82 |
|
|
2023
Q1 | $10.1M | Hold |
29,396
| – | – | 0.13% | 55 |
|
|
2022
Q4 | $10.8M | Sell |
29,396
-22,244
| -43% | -$7.89M | 0.14% | 60 |
|
|
2022
Q3 | $16.7M | Sell |
51,640
-32,319
| -38% | -$10.2M | 0.23% | 58 |
|
|
2022
Q2 | $27.2M | Sell |
83,959
-43,795
| -34% | -$13.1M | 0.34% | 52 |
|
|
2022
Q1 | $36.6M | Hold |
127,754
| – | – | 0.37% | 54 |
|
|
2021
Q4 | $35.3M | Hold |
127,754
| – | – | 0.32% | 53 |
|
|
2021
Q3 | $29.5M | Hold |
127,754
| – | – | 0.3% | 57 |
|
|
2021
Q2 | $29.3M | Buy |
127,754
+5,481
| +4% | +$1.1M | 0.31% | 52 |
|
|
2021
Q1 | $22.8M | Sell |
122,273
-30,696
| -20% | -$6M | 0.27% | 53 |
|
|
2020
Q4 | $25.8M | Buy |
152,969
+23,081
| +18% | +$3.45M | 0.34% | 52 |
|
|
2020
Q3 | $19.2M | Buy |
129,888
+72,299
| +126% | +$11.2M | 0.28% | 52 |
|
|
2020
Q2 | $9.46M | Hold |
57,589
| – | – | 0.15% | 64 |
|
|
2020
Q1 | $7.99M | Buy |
57,589
+13,049
| +29% | +$1.79M | 0.16% | 64 |
|
|
2019
Q4 | $5.85M | Hold |
44,540
| – | – | 0.09% | 90 |
|
|
2019
Q3 | $4.98M | Buy |
44,540
+17,136
| +63% | +$1.91M | 0.08% | 90 |
|
|
2019
Q2 | $3.04M | Buy |
27,404
+1,191
| +5% | +$140K | 0.05% | 109 |
|
|
2019
Q1 | $3.4M | Hold |
26,213
| – | – | 0.07% | 94 |
|
|
2018
Q4 | $3.03M | Sell |
26,213
-7,088
| -21% | -$792K | 0.07% | 93 |
|
|
2018
Q3 | $3.57M | Buy |
+33,301
| New | +$3.33M | 0.07% | 98 |
|
Other funds holding LLY
Sarasin & Partners's LLY Position: Q2 2026 in Review
Sarasin & Partners reduced its Eli Lilly (LLY) stake by 9.3% in Q2 2026, selling an estimated $11.6M and leaving 110,831 shares worth $133M. The position accounts for 1.56% of the portfolio, ranked #23.
Sarasin & Partners first reported a position in LLY in Q3 2018 and has held it in 31 quarters since. The position peaked at $285M in Q2 2024. 4,630 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Sarasin & Partners held 110,831 shares of Eli Lilly worth $133M as of Q2 2026.
- Sarasin & Partners sold 11,349 Eli Lilly shares in Q2 2026, an estimated $11.6M.
- Eli Lilly made up 1.56% of Sarasin & Partners's portfolio in Q2 2026, its #23 holding.
- Sarasin & Partners first reported a position in Eli Lilly in Q3 2018 and has held it in 31 quarters since.
- Sarasin & Partners's Eli Lilly position peaked at $285M in Q2 2024.
- 4,630 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Sarasin & Partners's 13F filing for Q2 2026, filed 7 Jul 2026.